174 related articles for article (PubMed ID: 30073390)
1. Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma.
Albertini MR; Yang RK; Ranheim EA; Hank JA; Zuleger CL; Weber S; Neuman H; Hartig G; Weigel T; Mahvi D; Henry MB; Quale R; McFarland T; Gan J; Carmichael L; Kim K; Loibner H; Gillies SD; Sondel PM
Cancer Immunol Immunother; 2018 Oct; 67(10):1647-1658. PubMed ID: 30073390
[TBL] [Abstract][Full Text] [Related]
2. Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2.
Yang RK; Kuznetsov IB; Ranheim EA; Wei JS; Sindiri S; Gryder BE; Gangalapudi V; Song YK; Patel V; Hank JA; Zuleger C; Erbe AK; Morris ZS; Quale R; Kim K; Albertini MR; Khan J; Sondel PM
Clin Cancer Res; 2020 Jul; 26(13):3296-3306. PubMed ID: 32152202
[TBL] [Abstract][Full Text] [Related]
3. Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: results from a multicentre, randomized clinical phase III trial.
Khammari A; Nguyen JM; Leccia MT; Guillot B; Saiagh S; Pandolfino MC; Knol AC; Quéreux G; Chiffolettau A; Labarrière N; Dréno B
Cancer Immunol Immunother; 2020 Aug; 69(8):1663-1672. PubMed ID: 32306076
[TBL] [Abstract][Full Text] [Related]
4. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
Osenga KL; Hank JA; Albertini MR; Gan J; Sternberg AG; Eickhoff J; Seeger RC; Matthay KK; Reynolds CP; Twist C; Krailo M; Adamson PC; Reisfeld RA; Gillies SD; Sondel PM;
Clin Cancer Res; 2006 Mar; 12(6):1750-9. PubMed ID: 16551859
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of hu14.18-IL2 for patients with metastatic melanoma.
Albertini MR; Hank JA; Gadbaw B; Kostlevy J; Haldeman J; Schalch H; Gan J; Kim K; Eickhoff J; Gillies SD; Sondel PM
Cancer Immunol Immunother; 2012 Dec; 61(12):2261-71. PubMed ID: 22678096
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma.
Hank JA; Gan J; Ryu H; Ostendorf A; Stauder MC; Sternberg A; Albertini M; Lo KM; Gillies SD; Eickhoff J; Sondel PM
Clin Cancer Res; 2009 Sep; 15(18):5923-30. PubMed ID: 19737959
[TBL] [Abstract][Full Text] [Related]
7. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma.
Ribas A; Kirkwood JM; Atkins MB; Whiteside TL; Gooding W; Kovar A; Gillies SD; Kashala O; Morse MA
J Transl Med; 2009 Jul; 7():68. PubMed ID: 19640287
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.
Yang RK; Kalogriopoulos NA; Rakhmilevich AL; Ranheim EA; Seo S; Kim K; Alderson KL; Gan J; Reisfeld RA; Gillies SD; Hank JA; Sondel PM
Cancer Immunol Immunother; 2013 Aug; 62(8):1303-13. PubMed ID: 23661160
[TBL] [Abstract][Full Text] [Related]
10. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.
Neal ZC; Yang JC; Rakhmilevich AL; Buhtoiarov IN; Lum HE; Imboden M; Hank JA; Lode HN; Reisfeld RA; Gillies SD; Sondel PM
Clin Cancer Res; 2004 Jul; 10(14):4839-47. PubMed ID: 15269160
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma.
Sharon CE; Tortorello GN; Ma KL; Huang AC; Xu X; Giles LR; McGettigan S; Kreider K; Schuchter LM; Mathew AJ; Amaravadi RK; Gimotty PA; Miura JT; Karakousis GC; Mitchell TC
Ann Oncol; 2023 Sep; 34(9):806-812. PubMed ID: 37414215
[TBL] [Abstract][Full Text] [Related]
12. Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.
Weber JS; Ascierto PA; Middleton MR; Hennicken D; Zoffoli R; Pieters A; Amadi A; Kupas K; Kotapati S; Moshyk A; Schadendorf D
Eur J Cancer; 2021 Nov; 158():225-233. PubMed ID: 34663559
[TBL] [Abstract][Full Text] [Related]
13. Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697).
Lawson DH; Lee S; Zhao F; Tarhini AA; Margolin KA; Ernstoff MS; Atkins MB; Cohen GI; Whiteside TL; Butterfield LH; Kirkwood JM
J Clin Oncol; 2015 Dec; 33(34):4066-76. PubMed ID: 26351350
[TBL] [Abstract][Full Text] [Related]
14. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.
Eggermont AMM; Kicinski M; Blank CU; Mandala M; Long GV; Atkinson V; Dalle S; Haydon A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Krepler C; Ibrahim N; Marreaud S; van Akkooi A; Robert C; Suciu S
JAMA Oncol; 2020 Apr; 6(4):519-527. PubMed ID: 31895407
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
Eggermont AM; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbé C; Ferraresi V; Smylie M; Weber JS; Maio M; Konto C; Hoos A; de Pril V; Gurunath RK; de Schaetzen G; Suciu S; Testori A
Lancet Oncol; 2015 May; 16(5):522-30. PubMed ID: 25840693
[TBL] [Abstract][Full Text] [Related]
17. [Adjuvant adoptive immunotherapy in patients with stage III and resected stage IV melanoma: a pilot study].
Verdecchia GM; Ridolfi L; Ridolfi R; Riccobon A; Bertagni A; Vagliasindi A; Petrini M; Stefanelli M; Milandri C; Amadori D
Tumori; 2003; 89(4 Suppl):298-300. PubMed ID: 12903626
[TBL] [Abstract][Full Text] [Related]
18. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
19. Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease.
Diem S; Hasan Ali O; Ackermann CJ; Bomze D; Koelzer VH; Jochum W; Speiser DE; Mertz KD; Flatz L
Cancer Immunol Immunother; 2018 Jan; 67(1):39-45. PubMed ID: 28894934
[TBL] [Abstract][Full Text] [Related]
20. The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.
Yamane BH; Hank JA; Albertini MR; Sondel PM
Expert Opin Investig Drugs; 2009 Jul; 18(7):991-1000. PubMed ID: 19548853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
